“The scientific team at Disarm discovered an important and highly promising approach to combat axonal degeneration. We will move quickly to develop their SARM1 inhibitors into potential medicines for peripheral neuropathy and neurological diseases, such as ALS and multiple sclerosis,” Mark Mintun, MD, vice president of pain and neurodegeneration research at Lilly, said in a press release.
https://alsnewstoday.com/news-posts/...aign=OneSignal
https://alsnewstoday.com/news-posts/...aign=OneSignal
Comment